Effectiveness of simvastatin/aspirin combination in the treatment of coronary heart disease in the elderly, and its effect on cardiac function and levels of inflammatory factors
Purpose: To investigate the efficacy of simvastatin plus aspirin in the treatment of coronary heart disease in the elderly, and its effect on cardiac function and inflammatory factor levels.
Methods: Eighty-seven identified elderly patients with coronary heart disease who were admitted to Nantong First People's Hospital, Nantong, China between January 2020 and June 2021 were recruited and assigned at a ratio of 1:1 to receive either conventional treatment (group A) or simvastatin plus aspirin (group B). The clinical endpoint was treatment efficacy.
Results: No significant differences were found between the two groups in respect of their baseline data (p > 0.05). Simvastatin plus aspirin was associated with a significantly higher treatment efficacy versus conventional treatment (p < 0.05). The patients, after joint therapy, had more cases of grade I cardiac function and fewer cases of grade III cardiac function, compared with conventional treatment group (p < 0.05). The application of simvastatin plus aspirin resulted in lower levels of triglycerides (TGs), total cholesterol (TC), fasting plasma glucose (FPG), low-density lipoprotein cholesterol (LDL-C), and highdensity lipoprotein cholesterol (HDL-C) than the conventional treatment (p < 0.05). Simvastatin plus aspirin was also associated with lower levels of interleukin (IL)-6 and hypersensitive-c-reactive-protein (hs-CRP) when compared with conventional treatment (p < 0.05). Furthermore, simvastatin plus aspirin produced a similar incidence of adverse events with conventional treatment (p > 0.05).
Conclusion: Simvastatin/aspirin combination therapy is effective in the treatment of coronary heart disease in the elderly. It efficiently lowers glucose levels, lipid metabolism, and inflammatory factors, but enhances the cardiac function of patients.
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.